Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer

Tas F., Karabulut S., Serilmez M., KARABULUT M., Duranyildiz D.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.77, no.1, pp.127-131, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 77 Issue: 1
  • Publication Date: 2016
  • Doi Number: 10.1007/s00280-015-2886-5
  • Journal Name: CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.127-131
  • Keywords: MCP-1/CCL-2, Serum, Gastric cancer, Predictive
  • Istanbul University Affiliated: Yes

Abstract

Monocyte chemoattractant protein 1 (MCP-1/CCL-2) is a member of the CC chemokine family and a potent chemotactic factor for monocytes that regulate migration and infiltration of monocytes and macrophages. It plays an important role in the pathogenesis of multiple malignancies, and its expression strongly also affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of MCP-1/CCL-2 in gastric cancer patients.